Clinical Trial Update: A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the combination of ibrutinib with bendamustine and rituximab in newly diagnosed mantle cell lymphoma has completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Ibrutinib (ibrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Mantle Cell Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2022-07-26